CAPRI
CAPRI
Evaluating the effectiveness of intravenous ciclosporin on reducing reperfusion injury in patients undergoing primary percutaneous coronary intervention: a double-blind, phase II, randomised controlled trial
• Status: Closed
• Sponsor: The Newcastle upon Tyne Hospitals NHS Foundation Trust
• Funder: NIHR Biomedical Research Centre (BRC)
• Therapeutic area: Cardiovascular
• Type of study: CTIMP
Aim: To determine the effect of ciclosporin treatment prior to PPCI on infarct size at 12 weeks relative to placebo treatment.
Primary Outcome: Infarct size at 12 weeks post-PPCI as measured by cardiac magnetic resonance imaging (MRI). Infarct size will be calculated as the percent of infarcted myocardium per LV mass.
• Clinical Phase: IIb
• Population: Adult
• Design: RCT
• Setting: Emergency Care
• Planned Sample Size: 68